Susan Schneider has a diverse background that spans the clinical, academic and corporate worlds. She has more than 10 years’ experience in clinical drug development and currently serves as Vice President and Therapeutic Area Head of Retina and Glaucoma at Allergan. Prior to joining Allergan, Susan was Vice President Retina, at Acucela, Sr. Medical Director at GlaxoSmithKline, Director, Clinical and Scientific Affairs for Ophthalmology at Bausch & Lomb, Vice President and Chief Medical Officer, US Clinical Affairs at Santen, and Medical Director at Genentech. While at Genentech, she worked extensively on the ranibizumab program. Susan has been involved in the launch of 3 ophthalmic products (Lucentis, Iquix, and Besivance) at 3 different companies.
Dr. Schneider received her medical degree from the Medical College of Pennsylvania followed by a residency in ophthalmology at the Medical College of Virginia. She completed fellowship training in ocular oncology at Thomas Jefferson Wills Eye Hospital and in ophthalmic pathology at The Johns Hopkins Wilmer Eye Institute. She has co-authored and published a number of articles for a variety of journals, including the New England Journal of Medicine, the American Journal of Ophthalmology and Ophthalmology Journal.
Dr. Schneider has held full time clinical and academic positions in the departments of ophthalmology and pathology at the New York Eye & Ear Infirmary and the University of Cincinnati. In addition, she was employed in a busy comprehensive ophthalmology practice in South Philadelphia after completing her training. Susan is excited to serve as a Trustee of the Glaucoma Service Foundation at Wills Eye Hospital.